942 results on '"Ghosh, Nilanjan"'
Search Results
2. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing
3. A new look at Integrated Water Resources Management from the perspective of scarcity value of water resources
4. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
5. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
6. Phytochemicals of Promise in the Management of Type 2 Diabetes Mellitus
7. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy
8. Role of Medicinal Plants in the Management of Diabetes Mellitus
9. Pharmacovigilance of Herbal Medicines for Lifestyle Diseases
10. Role of Natural Polysaccharides in the Management of Lifestyle Diseases
11. Herbal Medicines for the Treatment of Liver Cirrhosis
12. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry
13. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy
14. Finding structural requirements of structurally diverse α-glucosidase and α-amylase inhibitors through validated and predictive 2D-QSAR and 3D-QSAR analyses
15. Structural and molecular insights of protein tyrosine phosphatase 1B (PTP1B) and its inhibitors as anti-diabetic agents
16. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
17. COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients
18. Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).
19. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
20. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD
21. Governing the Himalayan Rivers in South Asia: A Review of the Challenges in the Ganges and the Brahmaputra Through the Lens of Paradigmatic Changes
22. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
23. Interlinking of Indian Rivers: Floated Myths, Flouted Realities
24. Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
25. Pharmacology to Practice
26. Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final Analysis of the Phase 2 PILOT Study
27. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001
28. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
29. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
30. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
31. Targeting mangiferin loaded N-succinyl chitosan-alginate grafted nanoparticles against atherosclerosis – A case study against diabetes mediated hyperlipidemia in rat
32. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
33. Challenges in Decision-Making for Building Resilience to Climate Risks
34. Water Disputes in the Cauvery and the Teesta Basins: Conflictual Federalism, Food Security, and Reductionist Hydrology
35. Pharmacology and Mechanisms of Natural Medicine in Treatment of Type 2 Diabetes Mellitus
36. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
37. Abstract 13062: In vivo Knockdown of Proapoptotic Mir-320 Restores Cardiac Function and Angiogenesis in a Mouse Model of Type 2 Diabetes
38. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
39. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
40. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
41. Phytopharmacology of herbal biomolecules
42. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
43. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study
44. Clean Water and Sanitation: India’s Present and Future Prospects
45. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
46. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
47. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
48. Wide Composite Resection of Sternal Metastasis & Reconstruction Using Titanium Mesh Implant and Myocutaneous Flap in Differentiated Thyroid Carcinoma: Case Report of Two Cases
49. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
50. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.